Regulator is exploring safety of immunotherapy combinations in blood cancer
Abraxane finally gets NHS funding following price cut.
Novocure’s Optune will be tested alongside investigational Celgene drug marizomib.
Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
Pharma begins early intervention trial after Cosentyx shows “disease modifying” properties
Guselkumab can also be used if older drug Stellara fails.